Astellas and Vir Biotechnology Announce $1.71 Billion Deal to Develop Prostate Cancer Drug

Feb 24, 2026

Astellas Pharma and Vir Biotechnology have entered into a global collaboration to develop and commercialize VIR-5500, an experimental treatment for prostate cancer. As part of the agreement, both companies will share development expenses and revenues.

Under the terms, Astellas will lead the commercialization of VIR-5500 in the U.S., while Vir has the option to co-promote the drug. Outside the U.S., Astellas will have exclusive commercialization rights.

Vir Biotechnology will receive $335 million in upfront and near-term milestone payments from Astellas. Additionally, Vir could earn up to $1.37 billion in future development, regulatory, and sales milestones. Vir will also receive a share of U.S. profits or losses and tiered royalties from sales outside the U.S.

Following this announcement, shares of Vir Biotechnology rose sharply, with investors responding positively to both the partnership and the company's recent financial performance.

What is VIR-5500?

VIR-5500 is an experimental drug being developed to treat prostate cancer.

How will Astellas and Vir Biotechnology share responsibilities?

Astellas will handle commercialization in the U.S. and globally outside the U.S., while both companies will jointly develop the drug and share expenses and revenues.

Why did Vir Biotechnology's stock price increase?

The stock rose after the partnership news with Astellas and strong recent financial results.

How much could Vir earn from this deal?

Vir is set to receive $335 million upfront and could earn up to $1.37 billion more, plus a share of profits and royalties.

Sources
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advanc...
PRNewsWire
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining option to co-promote, and Astellas will obtain exclusive rights to commercialize VIR...
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Reuters
Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.
Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas
Investors Business Daily
Vir stock catapulted late Monday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.
What's Happening With VIR Stock?
Forbes
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging Phase 1 results. This information, combined with an impressive revenue exceedance, is fostering consi...
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bulli...
Seeking Alpha
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones. Recent licensing d...
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Business Wire
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200...
Show All Sources
Other News
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett